GTPases: Druggable Targets for A Variety of Diseases (P41733)

Target Name: GTPase

NCBI ID: P41733

GTPase

Other Name(s): GTPase

GTPases: Druggable Targets for A Variety of Diseases

GTPase, also known as GTPase-activating protein (GAP), is a family of transmembrane proteins that play a crucial role in intracellular signaling. GTPases are a class of proteins that convert guanositol 5-phosph (GTP) to guanosine 2-phosph (GDP) using ATP as a source of energy. This conversion is reversible, and the resulting GDP can then act as a template for protein synthesis or can be phosphorylated and ubiquitinated for degradation.

GTPases are involved in a wide range of cellular processes, including vesicle traffic, cell signaling, and cell division. They are regulators of protein kinase (PK) activity and are involved in many cellular signaling pathways, including the regulation of cell growth, differentiation, and survival. GTPases are also involved in the regulation of ion channels, cytoskeletal dynamics, and DNA replication.

GTPases have been identified as potential drug targets for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Many of these drugs work by inhibiting GTPase activity or by modulating the activity of GTPases. These drugs can be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the challenges in targeting GTPases is the lack of specificity in their regulation by small molecules. GTPases are involved in a wide range of cellular processes and many different types of small molecules can affect their activity. Therefore, it is difficult to identify small molecules that specifically interact with GTPases.

In addition, GTPases are also involved in the regulation of many different signaling pathways, which can make them difficult to target. For example, the regulation of GTPases is involved in the regulation of cell growth, differentiation, and survival, which can make it difficult to target GTPases for diseases that are characterized by these processes, such as cancer.

Despite these challenges, research into GTPases is ongoing and there is growing interest in identifying new drug targets for GTPases. One approach that is being explored is the use of small molecules that can specifically interact with specific subtypes of GTPases. This approach is based on the idea that different subtypes of GTPases may have different properties and may be more or less responsive to certain small molecules.

Another approach that is being explored is the use of genetic tools, such as RNA interference, to knock down or activate GTPases. This approach allows researchers to study the regulation of GTPases and to identify new drug targets.

In addition, some researchers are using computational tools to predict the potential activity of small molecules against different subtypes of GTPases. This can help identify new drug targets that are likely to be effective and to identify potential liabilities for drugs that are currently being developed for other purposes.

Overall, GTPases are a complex family of proteins that play a crucial role in intracellular signaling. They are involved in a wide range of cellular processes and are potential drug targets for a variety of diseases. Further research is needed to identify new drug targets for GTPases and to develop effective therapies for these diseases.

Protein Name: GTPase (nonspecified Subtype)

The "GTPase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTPase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets